Market Flux Event
Eli Lilly's Retatrutide Delivers More Than Double the Weight Loss of Ozempic in Phase 3 Diabetes Trial
Read this in the Market Flux appEli Lilly's investigational drug retatrutide produced more than twice the average weight loss of Novo Nordisk's Ozempic at its highest approved dose in an 80-week Phase 3 trial enrolling 1,298 adults with type 2 diabetes. Participants on retatrutide 9 mg lost an average of 19.5% of body weight and those on 12 mg lost 20.9%, compared with 9.4% for Ozempic 2 mg. In absolute terms, the 12 mg dose translated to 47.4 pounds lost versus 20.9 pounds with Ozempic.
Retatrutide also outperformed on blood sugar control, reducing A1C by 2.2 percentage points at both doses, versus a 1.8-point reduction with Ozempic. The drug's tolerability profile was a relative weakness: treatment discontinuations due to side effects ran at 4.8% for the 9 mg dose and 7.9% for the 12 mg dose, compared with 2.7% for Ozempic. The efficacy figures assume patients continued on treatment without sustained use of additional diabetes medication.
Retatrutide remains unapproved and full trial results are pending publication. The results could strengthen Lilly's competitive position in the obesity and diabetes market against Novo Nordisk, though regulatory approval and the tolerability gap remain key hurdles.
© AI-generated summary is provided by Market Flux
Sources
- BioStocks$LLY Retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial. $NVO
- Business WireNovocure to Evaluate Tumor Treating Fields Therapy with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, to Treat Pancreatic Cancer Through Clinical Trial Collaboration and Supply Agreement
- TheTradeXchange$ADAG - Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte’s INCA33890 in Patients with Microsatellite Stable Colorectal Cancer
- NasdaqCellectis S.A. Presents Preclinical Data Highlighting Efficient APOC3 Editing and Marked Triglyceride Reduction with .HEAL-101 at ESGCT 2026
- Seeking AlphaLilly's retatrutide beats Novo’s Ozempic in late-stage trial
- WOLF_FinancialEli Lilly $LLY's retatrutide delivered more than twice the average weight loss of Ozempic’s highest approved dose in an 80-week Phase 3 trial involving 1,298 adults with type 2 diabetes. Average weight loss was 19.5% with retatrutide 9 mg and 20.9% with 12 mg, compared with 9.4% for Ozempic 2 mg. At the 12 mg dose, that translated to 47.4 pounds lost versus 20.9 pounds with Ozempic. Both retatrutide doses lowered A1C by 2.2 percentage points, versus 1.8 with Ozempic. Treatment discontinuations due to side effects were higher: 4.8% and 7.9% for retatrutide, compared with 2.7% for Ozempic. The efficacy estimates assume patients continued treatment without sustained use of additional diabetes medication. Retatrutide remains unapproved, and full results are pending publication.
- Newsfile CorpPharmaTher Submits Orphan Drug and Rare Pediatric Disease Designation Applications to FDA for 3D-Printed Creatine Monohydrate in GAMT Deficiency
- Newsfile_CorpPharmaTher Submits Orphan Drug and Rare Pediatric Disease Designation Applications to FDA for 3D-Printed Creatine Monohydrate in GAMT Deficiency Full Story: #Pharmather_Inc $PHRM.C #PHRM.CA #PHRRF #Chemicals #Pharmaceutical #Biotechnology #Medical
Show 7 more
- ReutersGeron discontinues late-stage trial of blood cancer drug
- OpenOutcrier$MLYS (+5.3% pre) Mineralys reports positive phase 2 CKD trial results
- AccesswireNews$TNON Tenon Medical(R) Announces Completion of Initial Alpha Cases of the New Quickstep(TM) Decorticator for the ...
- MarketsdayEli Lilly robinhood:0x8005d266423c7ea827372c9c864491e5786600ea : Retatrutide Delivers Over Twice the Weight Loss of Ozempic in Phase 3 Trial – October 28, 2026 🔹 Eli Lilly’s investigational drug retatrutide demonstrated substantially greater weight loss than semaglutide (Ozempic) 2 mg in an 80-week Phase 3 trial involving 1,298 adults with type 2 diabetes. 🔹 Average weight loss reached 19.5% with retatrutide 9 mg and 20.9% with the 12 mg dose, compared with 9.4% for Ozempic 2 mg. 🔹 At the 12 mg dose, participants lost an average of 47.4 pounds, versus 20.9 pounds with Ozempic. 🔹 A1C levels declined by 2.2 percentage points with both retatrutide doses, compared with a 1.8-point reduction with Ozempic. 🔹 Side-effect-related treatment discontinuations were higher with retatrutide: 4.8% at 9 mg and 7.9% at 12 mg, versus 2.7% with Ozempic. 🔹 The efficacy estimates assume patients continued treatment without sustained use of additional diabetes medication. 🔹 Retatrutide remains investigational and is not yet approved. Full trial results are pending publication. 🔹 Key takeaway: Retatrutide’s reported weight-loss and glucose-control results could strengthen Eli Lilly’s position in the obesity and diabetes treatment market, although tolerability, regulatory approval and full trial data remain important factors. #EliLilly #LLY #Retatrutide #Ozempic #ObesityTreatment #Diabetes #WeightLoss #Pharmaceuticals #HealthcareStocks #ClinicalTrials
- BPharmCatalyst$GERN discontinued its Phase 3 IMpactMF trial evaluating imetelstat in 327 subjects with JAK inhibitor-relapsed or refractory myelofibrosis. An independent monitoring committee determined the study was unlikely to demonstrate a primary overall survival benefit compared to best available therapy, with no new safety concerns identified. Consequently, Phase 3 myelofibrosis development has ceased, shifting commercial focus to RYTELO for lower-risk myelodysplastic syndromes, where U.S. and EU regulatory approvals remain active. $AXGN $RAPP $CDT $LUNG $BSX $NUWE $FIXX $GEHC $MTNB $SPRC See More Pre-market Movers at BioPharmCatalyst in the Articles Menu
- TheflynewsGeron to discontinue IMpactMF trial $GERN
- LiveSquawk$LLY | Lilly's Retatrutide Outshines Ozempic On Weight Loss, Blood Sugar Control In Trial – @Reuters